Search for: "Gilead Tenofovir Cases"
Results 1 - 20
of 37
Sorted by Relevance
|
Sort by Date
28 Oct 2017, 8:57 am
Anders ValentinJust as the case has been in other European jurisdictions, Gilead is currently attempting to enforce its (Danish) SPC for the combination of tenofovir disoproxil (as fumarate) and emtricitabine in Denmark. [read post]
25 Oct 2017, 9:02 am
", [2017] EWHC 13 (Pat)).Teva (or rather Mepha, its Swiss subsidiary) sought a declaration of invalidity of Gilead’s Swiss SPC for the combination of tenofovir disoproxil and emtricitabine. [read post]
17 Jan 2019, 6:50 am
Gilead Sciences vs Sandoz – Round Two Repeals of preliminary injunctions are seldom seen in Danish patent cases. [read post]
16 Jan 2024, 8:02 am
Gilead Tenofovir Cases, No. [read post]
5 Nov 2018, 12:24 am
The Court did not consider these criteria to be met in the case at hand, given that the basic patent underlying Gilead’s SPC merely referred to “other therapeutic ingredients” and failed to provide any more specific disclosure pointing to emtricitabine. [read post]
30 Mar 2013, 8:18 pm
In the present case, the CCI did not even find it necessary to refer the case to the DG or issue notice to Gilead and has instead directly rejected the case. [read post]
22 Dec 2020, 7:15 am
Based on SPC FR08C0020, Gilead decided to take action for infringement against Mylan, which launched TENOFOVIR DISOPROXIL, a generic of TRUVADA®. [read post]
25 Jul 2007, 12:42 pm
Patents Nos. 5,922,695, 5,935,946, 5,977,089 and 6,043,230, relate to the drug known generically as tenofovir disoproxil fumarate (TDF). [read post]
19 Dec 2019, 9:41 am
"So thus, Case C-121/17 was born. [read post]
20 Jun 2018, 4:12 am
’s Swiss SPC C00915894/01 for the combination of tenofovir disoproxil fumarate plus emtricitabine. [read post]
26 Apr 2018, 4:48 am
This case concerned an SPC Gilead had obtained for the combination of tenofovir and emtricitabine based upon Gilead’s patent, which claimed “A pharmaceutical composition comprising a compound according to any one of claims 1 to 25 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients”. [read post]
25 Jan 2017, 11:25 pm
As well as the TRUVADA® combination product, Gilead markets VIREAD®, a monotherapy (tenofovir), but has not obtained an SPC for it. [read post]
30 Jan 2024, 4:32 am
The active ingredient in Truvada is tenofovir disoproxil fumarate or “TDF” which was developed by Truvada’s manufacturer, Gilead Pharmaceuticals. [read post]
31 Mar 2017, 7:35 am
In the past three months, Mr Justice Arnold has decided three SPC cases - Teva v Gilead [2017] EWHC 13, Abraxis v Comptroller General of Patents [2017] EWHC 14 and, last week, Teva v MSD [2017] EWHC 539. [read post]
30 Apr 2019, 7:22 am
In that case Gilead’s SPC was for tenofovir plus emtricitabine, whereas the relevant patent claimed tenofovir and optionally “other therapeutic ingredients”. [read post]
27 Apr 2021, 1:53 am
Gilead Sciences (Case C-121/17) and Royalty Pharma v. [read post]
31 May 2018, 3:02 pm
The FDA approved generic Truvada in 2017, with Teva and Gilead making a deal. [read post]
31 Jul 2018, 7:58 am
Specifically, the case concerned Gilead’s SPC for the combination of tenofovir and emtricitabine. [read post]
1 Apr 2008, 2:32 am
There is no unitary European supplementary protection certificate, but national ones only.According to Burrows,In [in Re Gilead Sciences, Inc.] an application was made for an SPC in respect of EP (UK) 0 915 894 and the combination of two antiretroviral compounds, namely tenofovir disoproxil and emtricitabine. [read post]
23 Sep 2017, 7:02 am
THE SPC BLOGTenofovir - High Court Decision in France Those following the tenofovir SPC litigation in Europe will be pleased to hear that the High Court of Paris has recently handed down a decision in relation to Gilead's SPC based on EP0915894. [read post]
